Patient Guide · Genetics Explained · APOE Basics
APOE 2, 3, and 4: What the Three Versions of This Gene Actually Do
By Brian Paquette, DO, MPH
Everyone carries two copies of the APOE gene. They come in three versions, and the difference between them is remarkably small — a change in one or two building blocks out of 299. This guide explains what the gene does, how the three versions differ, and which numbers about risk are worth paying attention to.
What APOE Is For
The APOE gene contains the instructions for making a protein called apolipoprotein E. Think of that protein as a delivery vehicle for fat. Cholesterol and other fats do not dissolve in blood, so the body packages them into particles and attaches proteins that act as address labels. Apolipoprotein E is one of those labels. It tells the liver and other tissues where a fat particle should be delivered or removed.
In the brain, the same protein does related work. Brain cells need cholesterol to build and repair the connections between them. Apolipoprotein E made by support cells called astrocytes moves that material where it is needed, especially after injury. The brain makes its own supply; the version circulating in your bloodstream does not cross into it.
This protein also takes part in clearing amyloid, a protein fragment that accumulates in Alzheimer’s disease, and in the brain’s inflammatory and repair responses. That is the connection between a fat-transport gene and a memory disorder.
How Small the Difference Really Is
The protein is a chain of 299 building blocks called amino acids. The three versions of APOE differ at just two positions in that chain, numbered 112 and 158. One version has one amino acid there; another has a different one. Everything else about the protein is identical.
| Version | How common | What it tends to do |
| APOE 2 | Least common | Lowers the risk of Alzheimer’s disease and tends to lower LDL cholesterol. Its one drawback: it clears certain fat particles slowly, which in a small number of people leads to a treatable cholesterol disorder. |
| APOE 3 | Most common | The reference version. Everything else is described as higher or lower risk compared with two copies of this one. |
| APOE 4 | In between | The strongest common genetic risk factor for late-onset Alzheimer’s disease, and associated with an earlier average age of symptoms. Also tends to raise LDL cholesterol. |
Because you inherit one copy from each parent, there are six possible combinations. Yours might be written as 3/3, 3/4, 4/4, 2/3, 2/4, or 2/2 — or with the Greek letter epsilon, as ε3/ε4.
Why One Amino Acid Matters So Much
The two versions get into trouble in opposite ways, and it is worth understanding the difference because it explains a lot of what follows.
APOE 2 has a change right where the protein docks onto its receptor. The address label is smudged, so certain fat particles are not picked up efficiently and can build up in the blood.
APOE 4 docks onto its receptor perfectly well. Its problem is shape. The single amino acid change causes the two ends of the protein to fold back and stick to each other, which makes the molecule less stable and easier to break apart. Some of the resulting fragments appear to be harmful to nerve cells.
This distinction matters because it means the APOE 4 protein is not simply missing. Researchers are exploring whether a drug could nudge it back into the healthier shape. Nothing of that kind is available yet.
The Risk Numbers — and Which to Trust
If you search for APOE 4 online, you will find phrases like “raises your risk 12-fold.” That figure is misleading, and I want to explain why rather than simply replace it with a different number.
Those large multipliers come from studies that compared people already diagnosed with Alzheimer’s disease against people who were not. That design is useful for establishing that a gene matters. It is poor at estimating what will happen to any one person, because the people studied were recruited from memory clinics and brain donation programs — not from the general population.
When researchers instead followed ordinary community populations over decades — the long-running Framingham and Rotterdam studies — the picture was considerably less dramatic. Among people who carried two copies of APOE 4 and were cognitively healthy in their sixties, roughly a third developed mild cognitive impairment or dementia by their early eighties (Qian et al., PLoS Medicine, 2017, DOI). That is a meaningful elevation. It is not a certainty, and it is not twelve times anything.
A more useful way to think about it: a large 2024 study found that people with two copies of APOE 4 almost all develop the biological changes of Alzheimer’s disease, and that symptoms, when they appear, begin at a median age of 65 — earlier and more predictably than in other genotypes (Fortea et al., Nature Medicine, DOI). Timing and biology, rather than a multiplier, is the honest framing.
One further caution: nearly all of these figures come from people of European ancestry, and the effect of APOE 4 is measurably different in other populations. We cover that in detail in APOE ε4 Risk Is Not the Same in Every Population.
What About Cholesterol and the Heart?
Your APOE version does shift your LDL cholesterol. Across nearly 86,000 healthy people, LDL rose steadily from the lowest-risk combination to the highest, with about a 31% difference between the two extremes (Bennet et al., JAMA, 2007, DOI).
Whether that translates into more heart attacks is a different question, and the answer is more reassuring than you might expect. In the same analysis, carrying APOE 2 clearly lowered coronary risk. Carrying APOE 4 raised it only slightly, by an amount small enough that it could have been chance. So if you carry APOE 4, the sensible reading is not “I have a heart gene problem.” It is “I should know my LDL number, because my genotype nudges it upward and LDL is something we can treat.”
If Your Result Says 2/2
Two copies of APOE 2 is the most protective combination for Alzheimer’s risk. It carries one specific liability: a cholesterol disorder called type III hyperlipoproteinemia, in which both cholesterol and triglycerides run high. Importantly, most people with 2/2 never develop it. It requires an additional trigger — often weight gain, diabetes, an underactive thyroid, or alcohol — and it responds well to treatment. A 2/2 result is a reason to have a fasting lipid panel checked, not a reason for alarm.
What This Means for You
1. APOE is a risk gene, not a diagnosis. It changes probabilities. It does not determine an outcome, and many people with two copies of APOE 4 live into their eighties without dementia.
2. Be sceptical of fold-change numbers. Ask instead what percentage of people like you developed the condition, and over what span of years.
3. Know your LDL cholesterol. This is the one part of the APOE story that is directly measurable and directly treatable today.
4. Bring the result to a clinician. A consumer genetics report is not a medical record, and the interpretation depends on your age, family history, ancestry, and other health conditions.
What This Article Cannot Tell You
- Your personal risk. The figures here are group averages, drawn largely from people of European ancestry, and carry wide margins of uncertainty.
- Whether anything you do will change your outcome. Lifestyle research is promising and worth acting on, but no trial has yet shown that any intervention prevents dementia in APOE 4 carriers specifically.
- Everything in your APOE gene. Standard testing looks at two positions only. Rarer changes elsewhere in the gene can alter risk and will not appear on a consumer report.
If you want the next level of detail — genotype-by-genotype risk figures and what they were derived from — see APOE4 Risk by Genotype.
EDITORIAL NOTE: All citations verified against the primary source record via PubMed. Educational content only; not a substitute for individual clinical judgement.